Skip to main content
. 2022 Oct 26;14(21):5243. doi: 10.3390/cancers14215243

Table 4.

Univariable and multivariable logistic regression.

Population Characteristics Univariable Logistic Regression 1 Multivariable Logistic Regression 2
X2 = 1106.36 (p-Value < 0.001)
Nagelkerke R2 = 0.47
OR [95%CI] p-Value OR [95%CI] p-Value
Age at questionnaire 0.99 [0.98–1.01] 0.318
Gender Male Reference Reference
Female 3.54 [2.80–4.46] <0.001 3.79 [2.49–5.77] <0.001
Partner Yes Reference Reference
No 2.05 [1.65–2.54] <0.001 1.17 [0.88–1.57] 0.284
Level of education Low 2.40 [0.94–6.09] 0.067 1.91 [0.43–8.49] 0.398
Medium 1.51 [1.25–1.81] <0.001 1.13 [0.88–1.44] 0.336
High Reference Reference
Type of cancer Melanoma Reference Reference
Head and neck 1.55 [0.72–3.34] 0.260 1.68 [0.64–4.30] 0.283
Colon and rectal 1.57 [0.65–3.76] 0.313 0.97 [0.31–2.90] 0.922
Digestive tract other 3 3.33 [1.21–9.20] 0.020 3.92 [0.98–15.60] 0.053
Breast 3.67 [2.21–6.08] <0.001 2.51 [1.19–5.28] 0.015
Female genitalia 3.89 [2.29–6.63] <0.001 3.15 [1.59–6.24] <0.001
Thyroid gland 1.72 [0.92–3.22] 0.093 0.81 [0.36–1.83] 0.609
Central nervous system 2.44 [1.26–4.73] 0.008 1.00 [0.33–3.03] 0.996
Bone and soft tissue sarcoma 1.84 [0.94–3.59] 0.074 1.82 [0.77–4.29] 0.170
Germ cell tumor 0.82 [0.46–1.47] 0.513 2.51 [1.11–5.65] 0.027
Lymphoid hematological malignancies 2.12 [1.24–3.62] 0.006 2.10 [0.98–4.49] 0.055
Myeloid hematological malignancies 2.35 [1.21–4.58] 0.012 1.78 [0.60–5.32] 0.303
Other 4 2.10 [0.95–4.64] 0.069 1.20 [0.43–3.33] 0.732
Tumor stage I Reference Reference
II 1.58 [1.26–1.97] <0.001 1.49 [1.07–2.10] 0.020
III 1.44 [1.09–1.89] 0.010 1.72 [1.13–2.61] 0.012
IV 1.45 [0.94–2.23] 0.093 1.73 [0.92–3.25] 0.087
Missing 1.20 [0.88–1.64] 0.239 1.35 [0.68–2.70] 0.390
Chemotherapy 5 No Reference Reference
Yes 1.40 [1.16–1.69] <0.001 0.68 [0.47–0.99] 0.041
Radiotherapy 5,6 No Reference Reference
Yes 1.43 [1.19–1.72] <0.001 1.12 [0.85–1.47] 0.430
Hormone therapy 5 No Reference Reference
Yes 2.21 [1.74–2.79] <0.001 1.22 [0.81–1.83] 0.348
Targeted therapy 5 No Reference Reference
Yes 1.36 [1.00–1.86] 0.053 0.97 [0.63–1.50] 0.905
Surgery organ 5 No Reference
Yes 1.09 [0.90–1.32] 0.398
Surgery local 5 No Reference
Yes 0.85 [0.65–1.12] 0.248
Stem cell transplantation 5 No Reference
Yes 1.37 [0.79–2.36] 0.260
Time since diagnosis <10 years 1.45 [1.16–1.82] 0.001 1.26 [0.94–1.69] 0.129
10–15 years 1.03 [0.81–1.31] 0.799 0.92 [0.68–1.24] 0.570
>15 years Reference Reference
Physical activity MET hours/week 1.00 [1.00–1.00] 0.131
BMI Underweight 1.86 [0.95–3.63] 0.071 0.75 [0.31–1.81] 0.516
Normal weight Reference Reference
Overweight 1.26 [1.02–1.56] 0.034 1.70 [1.29–2.24] <0.001
Obesity 3.61 [2.82–4.61] <0.001 3.69 [2.66–5.13] <0.001
Maladaptive coping style 1.19 [1.16–1.22] <0.001 1.10 [1.06–1.13] <0.001
HRQoL Physical functioning 0.95 [0.95–0.96] <0.001 1.00 [0.99–1.00] 0.306
Role functioning 0.97 [0.96–0.97] <0.001 0.99 [0.99–1.00] 0.009
Emotional functioning 0.95 [0.94–0.95] <0.001 0.97 [0.97–0.98] <0.001
Cognitive functioning 0.97 [0.96–0.97] <0.001 0.99 [0.99–1.00] 0.006
Social functioning 0.96 [0.96–0.97] <0.001 0.99 [0.98–1.00] 0.001
Global Health status 0.95 [0.94–0.95] <0.001 0.98 [0.97–0.99] <0.001
Sexual attractiveness No Reference Reference
Yes 5.66 [4.05–7.91] <0.001 3.73 [2.50–5.57] <0.001

1 Univariable: p-value < 0.1 is included in multivariable analyses. 2 Multivariable: p-value < 0.05 is significant (bold p-values show a statistically significant OR). Method = enter. The multivariable model showed no multicollinearity. 3 Digestive tract and other includes the esophagus, stomach, and small intestine. 4 Other includes respiratory, male genitalia (penis, prostate), urinary tract, tumor with other localizations, endocrine glands, eye, neuroblastoma, paraganglioma. 5 The treatments were received at primary diagnosis. 6 Radiotherapy includes radiotherapy for primary tumor and metastases at primary diagnosis. OR [95%CI] = odds ratio and 95% confidence interval.